دورية أكاديمية
A Pharmacovigilance Analysis of Daptomycin Use Based on CLSI Susceptible Dose-Dependent Category.
| العنوان: | A Pharmacovigilance Analysis of Daptomycin Use Based on CLSI Susceptible Dose-Dependent Category. |
|---|---|
| المؤلفون: | Zhang MM; Department of Pharmacy, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA., Stevens RW; Department of Pharmacy, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA., Adema JL; Department of Pharmacy, East Carolina University Health Medical Center, 2100 Stantonsburg Rd., Greenville, NC, 27834, USA., Mara KC; Department of Quantitative Health Sciences, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA., Schuetz AN; Laboratory Medicine and Pathology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA., Tande AJ; Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA., Rivera CG; Department of Pharmacy, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA. rivera.christina@mayo.edu. |
| المصدر: | Infectious diseases and therapy [Infect Dis Ther] 2023 Sep; Vol. 12 (9), pp. 2295-2305. Date of Electronic Publication: 2023 Sep 26. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Adis Country of Publication: New Zealand NLM ID: 101634499 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8229 (Print) Linking ISSN: 21936382 NLM ISO Abbreviation: Infect Dis Ther Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2014- : [Auckland] Adis Original Publication: [London] : Springer Healthcare |
| مستخلص: | Introduction: Daptomycin doses 8-12 mg/kg are recommended for susceptible dose-dependent Enterococcus species. However, data remain limited on safety outcomes of such dosing, compared to standard 4-6 mg/kg dosing. Methods: In this retrospective cohort study, patients were stratified into daptomycin standard-dose (≤ 6.5 mg/kg) versus high-dose (≥ 7.5 mg/kg) groups. The primary outcome was daptomycin safety based on a composite of creatine kinase elevation, daptomycin-related peripheral blood eosinophilia, eosinophilic pneumonitis, alanine aminotransferase elevation, and alkaline phosphatase elevation. A secondary aim was to identify risk factors for daptomycin adverse effects. Inclusion criteria were age ≥ 18 years old, daptomycin receipt for ≥ 48 h, and Enterococcus cultures with a daptomycin minimal inhibitory concentration 2-4 mg/L. Results: A total of 119 patients were included for analysis. Median daptomycin doses were 6.0 mg/kg (IQR 5.4, 6.1) and 8.1 mg/kg (IQR 7.9, 9.6) in the standard- and high-dose cohorts, respectively. Median durations were 13.5 days (standard-dose) and 16 days (high-dose) (p = 0.02). The composite safety endpoint occurred in 32.0% of the standard-dose group and 32.5% of the high-dose group (p = 0.96). Daptomycin was dose-reduced or held in 8.1% of patients experiencing an adverse effect. Concurrent antihistamine usage was associated with the composite outcome; however, there was no association with daptomycin dose or concurrent statin use. Conclusion: High-dose daptomycin was not associated with increased laboratory abnormalities or adverse drug reactions compared to standard-dose daptomycin. (© 2023. The Author(s).) |
| References: | J Clin Microbiol. 2019 May 24;57(6):. (PMID: 30971460) J Antimicrob Chemother. 2018 Sep 1;73(9):2277-2283. (PMID: 29547977) Clin Infect Dis. 2020 Mar 3;70(6):1240-1246. (PMID: 31504338) Open Forum Infect Dis. 2021 Nov 10;8(12):ofab568. (PMID: 34888403) Clin Infect Dis. 2017 Mar 1;64(5):605-613. (PMID: 28011602) J Microbiol Immunol Infect. 2018 Dec;51(6):705-716. (PMID: 29046248) J Antimicrob Chemother. 2022 Jul 28;77(8):2278-2287. (PMID: 35639586) Int J Mol Sci. 2015 Dec 24;17(1):. (PMID: 26712744) Infect Control Hosp Epidemiol. 2011 Apr;32(4):391-4. (PMID: 21460492) Open Forum Infect Dis. 2022 Mar 16;9(4):ofac065. (PMID: 35308486) Drug Saf. 2012 Jun 1;35(6):447-57. (PMID: 22612850) Clin Infect Dis. 2018 Oct 15;67(9):1356-1363. (PMID: 29668884) Clin Infect Dis. 2017 Apr 15;64(8):1026-1034. (PMID: 28329222) |
| فهرسة مساهمة: | Keywords: Daptomycin; Enterococcus; Pharmacovigilance; Susceptible dose-dependent |
| تواريخ الأحداث: | Date Created: 20230926 Latest Revision: 20231020 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10581971 |
| DOI: | 10.1007/s40121-023-00868-0 |
| PMID: | 37751018 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2193-8229 |
|---|---|
| DOI: | 10.1007/s40121-023-00868-0 |